



Please type a plus sign (+) inside this box 

PTO/SB/05 (03-01)  
Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. <b>VPI/00-129-3 DIV US</b>	
		First Inventor <b>David Bebbington</b>	
		Title <b>Pyrazole Compounds Useful as Protein Kinase Inhibitors</b>	
		Express Mail Label No. <b>EV 317 172 745 US</b>	
<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>		<b>ADDRESS TO:</b> MS Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
<div>1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original, and a duplicate for fee processing)</small></div> <div>2. <input type="checkbox"/> Applicant claims small entity status. <small>See 37 CFR 1.27.</small></div> <div>3. <input checked="" type="checkbox"/> Specification <span style="float: right;">[Total Pages <b>353</b>]</span> <small>(preferred arrangement set forth below)</small><ul style="list-style-type: none"><li>- Descriptive title of the invention</li><li>- Cross Reference to Related Applications</li><li>- Statement Regarding Fed sponsored R &amp; D</li><li>- Reference to sequence listing, a table, or a computer program listing appendix</li><li>- Background of the Invention</li><li>- Brief Summary of the Invention</li><li>- Brief Description of the Drawings (if filed)</li><li>- Detailed Description</li><li>- Claim(s)</li><li>- Abstract of the Disclosure</li></ul></div> <div>4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) <span style="float: right;">[Total Sheets <b>5</b>]</span></div> <div>5. Oath or Declaration <span style="float: right;">[Total Pages <b>5</b>]</span><div>a. <input type="checkbox"/> Newly executed (original or copy)</div><div>b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 18 completed)</small><div>i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</small></div></div></div> <div>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</div>		<div>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)</div> <div>8. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small><div>a. <input type="checkbox"/> Computer Readable Form (CRF)</div><div>b. Specification Sequence Listing on:<div>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</div><div>ii. <input type="checkbox"/> paper</div></div><div>c. <input type="checkbox"/> Statements verifying identity of above copies</div></div>	
<b>ACCOMPANYING APPLICATIONS PARTS</b>			
<div>9. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</div> <div>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <span style="float: right;"><input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small></span></div> <div>11. <input type="checkbox"/> English Translation Document (if applicable)</div> <div>12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <span style="float: right;"><input type="checkbox"/> Copies of IDS Citations</span></div> <div>13. <input checked="" type="checkbox"/> Preliminary Amendment</div> <div>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small></div> <div>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small></div> <div>16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). <small>Applicant must attach form PTO/SB/35 or its equivalent.</small></div> <div>17. <input checked="" type="checkbox"/> Other: <b>Express Mail Page</b></div>			
<div>18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:<div><input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: <b>09/952,671</b></div><div>Prior application information: Examiner <b>Thomas C. McKenzie</b> Group / Art Unit: <b>1624</b></div></div> <div>For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.</div>			
<b>19. CORRESPONDENCE ADDRESS</b>			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		 <b>27916</b>	
Name <b>Andrea L. C. Robidoux</b>		PATENT TRADEMARK OFFICE	
Address <b>Vertex Pharmaceuticals Incorporated</b>			
City <b>Cambridge</b>		State <b>Massachusetts</b>	Zip Code <b>02139-4242</b>
Country <b>USA</b>	Telephone <b>(617) 444-6731</b>	Fax <b>(617) 444-6483</b>	
Name (Print/Type) <b>Andrea L. C. Robidoux</b>		Registration No. (Attorney/Agent) <b>47,902</b>	
Signature 		Date <b>July 22, 2003</b>	

10/624800  
07/22/03

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Patent fees are subject to annual revision.**

☐ Applicant claims small entity status. See 37 CFR 1.27

**Complete if Known**

<b>Application Number</b>	Not Yet Assigned
<b>Filing Date</b>	Herewith
<b>First Named Inventor</b>	David Bebbington
<b>Examiner Name</b>	Thomas McKenzie
<b>Group Art Unit</b>	1624
<b>Attorney Docket No.</b>	VPI/00-129-3 DIV US

**METHOD OF PAYMENT** (check all that apply)

<input type="checkbox"/>	Check	<input type="checkbox"/>	Credit Card	<input type="checkbox"/>	Money Order	<input type="checkbox"/>	Other	<input type="checkbox"/>	None
--------------------------	-------	--------------------------	-------------	--------------------------	-------------	--------------------------	-------	--------------------------	------

☒ Deposit Account

**Deposit  
Account  
Number**

50-0725

Deposit  
Account  
Name

Vertex Pharmaceuticals

**The Commissioner is hereby authorized to:** (check all that apply)

<input checked="" type="checkbox"/>	Charge fee(s) indicated below	<input checked="" type="checkbox"/>	Credit any overpayments
-------------------------------------	-------------------------------	-------------------------------------	-------------------------

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee

to the above-identified deposit account.

### FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity	Small Entity
<p>1. <b>Revenue Recognition</b></p> <p>Large entities use the <b>percentage of completion</b> method for long-term contracts, recognizing revenue as work progresses. Small entities often use the <b>cost of sales</b> method, recognizing revenue only when the contract is completed.</p>	<p>1. <b>Revenue Recognition</b></p> <p>Small entities often use the <b>cost of sales</b> method for long-term contracts, recognizing revenue only when the contract is completed.</p>
<p>2. <b>Inventory Valuation</b></p> <p>Large entities use the <b>FIFO</b> (First In, First Out) method for inventory valuation. Small entities often use the <b>LIFO</b> (Last In, First Out) method.</p>	<p>2. <b>Inventory Valuation</b></p> <p>Small entities often use the <b>LIFO</b> (Last In, First Out) method for inventory valuation.</p>
<p>3. <b>Depreciation</b></p> <p>Large entities use the <b>MACRS</b> (Modified Accelerated Cost Recovery System) for depreciation. Small entities often use the <b>straight-line</b> method.</p>	<p>3. <b>Depreciation</b></p> <p>Small entities often use the <b>straight-line</b> method for depreciation.</p>
<p>4. <b>Bad Debt Expense</b></p> <p>Large entities use the <b>allowance method</b> for bad debt expense. Small entities often use the <b>direct write-off</b> method.</p>	<p>4. <b>Bad Debt Expense</b></p> <p>Small entities often use the <b>direct write-off</b> method for bad debt expense.</p>
<p>5. <b>Lease Accounting</b></p> <p>Large entities use the <b>ASC 842</b> (Leases) standard for lease accounting. Small entities often use the <b>ASC 840</b> (Leases) standard.</p>	<p>5. <b>Lease Accounting</b></p> <p>Small entities often use the <b>ASC 840</b> (Leases) standard for lease accounting.</p>

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	750.00
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

<b>SUBTOTAL (1)</b>	<b>(\$)</b>	<b>750.00</b>
---------------------	-------------	---------------

## 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

			Extra Claims	Fee from below	Fee Paid
Total Claims	20	-20** =	0	18.00	0.00
Independent Claims	1	-3** =	0	84.00	0.00
Multiple Dependent				280.00	280.00

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

<b>SUBTOTAL (2)</b>	<b>(\$)</b>	<b>280.00</b>
---------------------	-------------	---------------

**\*\*or number previously paid, if greater; For Reissues, see above**

**FEE CALCULATION** (continued)

### 3. ADDITIONAL FEES

Large Entity	Small Entity
<p>1. <b>Revenue Recognition</b></p> <p>Large entities use the <b>percentage of completion</b> method for long-term contracts, recognizing revenue as work progresses. Small entities often use the <b>cost of sales</b> method, recognizing revenue only when the contract is completed.</p>	<p>1. <b>Revenue Recognition</b></p> <p>Small entities often use the <b>cost of sales</b> method for long-term contracts, recognizing revenue only when the contract is completed.</p>
<p>2. <b>Inventory Valuation</b></p> <p>Large entities use the <b>FIFO</b> (First In, First Out) method for inventory valuation. Small entities often use the <b>LIFO</b> (Last In, First Out) method.</p>	<p>2. <b>Inventory Valuation</b></p> <p>Small entities often use the <b>LIFO</b> (Last In, First Out) method for inventory valuation.</p>
<p>3. <b>Depreciation</b></p> <p>Large entities use the <b>MACRS</b> (Modified Accelerated Cost Recovery System) for depreciation. Small entities often use the <b>straight-line</b> method.</p>	<p>3. <b>Depreciation</b></p> <p>Small entities often use the <b>straight-line</b> method for depreciation.</p>
<p>4. <b>Bad Debt Expense</b></p> <p>Large entities use the <b>allowance method</b> for bad debt expense. Small entities often use the <b>direct write-off</b> method.</p>	<p>4. <b>Bad Debt Expense</b></p> <p>Small entities often use the <b>direct write-off</b> method for bad debt expense.</p>
<p>5. <b>Research and Development</b></p> <p>Large entities use the <b>capitalization</b> method for research and development costs. Small entities often use the <b>expensing</b> method.</p>	<p>5. <b>Research and Development</b></p> <p>Small entities often use the <b>expensing</b> method for research and development costs.</p>

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge – late filing fee or oath	
1052	50	2052	25	Surcharge – late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive – unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

<b>SUBTOTAL (3)</b>	<b>(\$)</b>	<b>0.00</b>
---------------------	-------------	-------------

## SUBMITTED BY

Name (Print/Type)

Andrea L-C Robidan

Registration No.  
(Attorney/Agent)

47,902

Complete (if applicable)

Telephone (647) 444-6731

Date \_\_\_\_\_

7/22/03

Docket No.: VPI/00-129-3 DIV US

**Certificate Of Mailing Under 37 C.F.R. § 1.10**

Express Mailing No. EV 317 172 745 US

Date of Deposit: July 22, 2003


I hereby certify that the following documents:

1. Utility Patent Application Transmittal;
2. Fee Transmittal Sheet (in duplicate);
3. Preliminary Amendment (w/exhibits 1 and 2);
4. Copy of Specification 353 pages (Desc 342 pgs., Claims 10 pgs., Abstract 1 pg);
5. Copy of Executed Declaration Power of Attorney Document (5 pages);
6. Information Disclosure Statement (in duplicate);
7. PTO-1449 Form (in duplicate); and
8. This Return Postcard Receipt.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Mailstop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Karen DiRocco

(type or printed name of person mailing document(s))



(signature of person mailing document(s))